WEB Biotechnology makes wireless ECG a reality

Updated on 10 May 2012

Benefits

Currently, patients in different hospitals, who are using Spyder are comfortable with the product as it has helped them to move around while their ECG imaging is constantly monitored. The light weight of the product, 26 grams as compared to 500 grams of other such heart rate tracking devices, enables hassle free mobility.

Besides checking the heart rate it has other benefits such as, with enhancements attached, it can read the calorie level needed to be reduced by patients after a cardiac surgery. To keep a stringent check, it can send an alarm to the hand phone when there is an increase in calorie level.
Mr Dominic Puah, CEO, Dr Philip Wong, medical director, WEB Biotechnology are keen to explore the markets of the US and Europe and are already in active discussion with the companies in countries from South-East Asia.
Currently, this device is not sold directly to the patients and is released on lease basis.

"No devices of such nature are for direct sale to patients. They are usually leased out to patients. In Singapore, a 24 hour recorded ECG with Spyder will cost about 200 SGD dollars in comparison to 500 SGD by other companies. Interpreting the critical requirement of this device, we prefer to lease out these devices through doctors, who can help patients understand what the sensors are recording," explained Dr Philip Wong.

On receiving the award, Mr Dominic Puah, CEO of WEB Biotechnology mentioned, "WEB Biotechnologies is extremely honored to receive such an award for Spyder. It confirms our vision that Spyder's unique qualities like its lightweight design, wireless connectivity and re-usability are desirable in the healthcare sector. WEB Biotechnologies will continue to develop other light weight sensors that are inconspicuous, and benefit patients who require continuous monitoring but are still mobile and wish to continue their daily activities."

Profiles of other winners

Selection criteria

Previous 1 2 Next

Leave a Reply

Notify me of follow-up comments via e-mail address

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X